| Overall (n = 564) | de novo (n = 485) | sAML (n = 79) |
---|---|---|---|
Original disease | 201 (37.2%) | 169 (36.3%) | 32 (42.1%) |
Infection | 162 (29.9%) | 142 (30.5%) | 20 (26.3%) |
GVHD | 75 (13.9%) | 68 (14.6%) | 7 (9.2%) |
Non HSCT related | 34 (6.3%) | 26 (5.6%) | 8 (10.5%) |
Other transp related | 17 (3.1%) | 17 (3.7%) | 0 (0%) |
MOF | 14 (2.6%) | 11 (2.4%) | 3 (3.9%) |
VOD | 10 (1.8%) | 10 (2.2%) | 0 (0%) |
Cardiac toxicity | 7 (1.3%) | 6 (1.3%) | 1 (1.3%) |
Other second malignancy | 6 (1.1%) | 5 (1.1%) | 1 (1.3%) |
Haemorhage | 6 (1.1%) | 4 (0.9%) | 2 (2.6%) |
Failure/Rejection | 4 (0.7%) | 3 (0.6%) | 1 (1.3%) |
CNS toxicity | 4 (0.7%) | 3 (0.6%) | 1 (1.3%) |
IP | 1 (0.2%) | 1 (0.2%) | 0 (0%) |
Missing | 23 | 20 | 3 |